Causa inusual de uropatía obstructiva: condrosarcoma pélvico
DOI:
https://doi.org/10.48193/revistamexicanadeurologa.v82i2.813Palabras clave:
Uropatía obstructiva, condrosarcoma mesenquimatoso, sarcoma de tejidos blandosResumen
Reportamos el caso de un paciente masculino de 37 años que presentó deterioro de la función renal secundario a tumoración pélvica. El abordaje diagnóstico reveló una tumoración dependiente del pubis correspondiente a un condrosarcoma mesenquimatoso que condicionaba obstrucción de la vía urinaria en los segmentos ureterales distales de manera bilateral, así como compresión vesical y sigmoidea. Los condrosarcomas mesenquimatosos son sarcomas dependientes de tejidos blandos con una incidencia extremadamente rara, la importancia clínica de nuestro reporte se debe a que los condrosarcomas, deben ser considerados en los diagnósticos diferenciales de uropatía obstructiva debido a su efecto compresor del tracto urinario. Realizamos un breve recuento del abordaje diagnóstico, plan terapéutico y pronóstico de esta patología.
Referencias
Lichtenstein L, Bernstein D. Unusual benign and malignant chondroid tumors of bone. A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer. 1959;12(6):1142–57. doi: https://doi.org/10.1002/1097-0142(195911/12)12:6<1142::AID-CNCR2820120610>3.0.CO;2-D
Lin O,, Zakowski MF. Cytology of Soft Tissue, Bone, and Skin. In: Comprehensive Cytopathology. 3rd ed. Elsevier; 2008. p. Philadelphia.
Ghafoor S, Hameed MR, Tap WD, Hwang S. Mesenchymal chondrosarcoma: imaging features and clinical findings. Skeletal Radiol. 2021;50(2):333–41. doi: https://doi.org/10.1007/s00256-020-03558-x
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2018;29:iv51–67. doi: https://doi.org/10.1093/annonc/mdy096
Wein AJ, M.D AWP, M.D LRK, Novick AC. Campbell-Walsh Urologia/ Campbell-Walsh Urology. 11th ed. Ed. Médica Panamericana; 2008. 808 p.
Xu J, Li D, Xie L, Tang S, Guo W. Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years. PLOS ONE. 2015 Apr 7;10(4):e0122216. doi: https://doi.org/10.1371/journal.pone.0122216
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer. 2015;51(3):374–81. doi: https://doi.org/10.1016/j.ejca.2014.11.007
Tsavaris O, Economopoulou P, Kotsantis I, Reppas L, Avgerinou C, Spathas N, et al. Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature. Frontiers in Oncology. 2018;8. doi: https://doi.org/10.3389/fonc.2018.00045
Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC. Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer. 1986;57(12):2444–53. doi: https://doi.org/10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K
Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes, Chromosomes and Cancer. 2012;51(2):127–39. doi: https://doi.org/10.1002/gcc.20937
Shapeero LG, Vanel D, Couanet D, Contesso G, Ackerman LV. Extraskeletal mesenchymal chondrosarcoma. Radiology. 1993;186(3):819–26. doi: https://doi.org/10.1148/radiology.186.3.8430193
Mendenhall WM, Reith JD, Scarborough MT, Stechmiller BK, Mendenhall NP. Mesenchymal Chondrosarcoma. Int J Part Ther. 2016;3(2):300–4. doi: https://doi.org/10.14338/IJPT-16-00019.1
Tansir G, Rastogi S, Barwad A, Dhamija E. Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma. Clinical Sarcoma Research. 2020;10(1):16. doi: https://doi.org/10.1186/s13569-020-00138-4
Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16(4):406–16. doi: https://doi.org/10.1016/S1470-2045(15)70098-7
Araki N, Takahashi S, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. European Journal of Cancer. 2016;56:122–30. doi: https://doi.org/10.1016/j.ejca.2015.12.014
Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007;93(5):423–7.
Publicado
Número
Sección
Licencia
Derechos de autor 2022 Revista Mexicana de Urología
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.